Influence of Low Dose rIL-2 Treatment on Endogenous Cytokine Production, Expression of Surface IL-2R and The Level of Soluble IL-2R in Patients With Minimal Residual Disease

References

• Smith K. A. Interleukin-2: inception, impact and implications. Science 1988; 240: 1169–1176
   PubMed Web of Science ®Google Scholar
• Farace F., Angevin E., Dietrich P. Y., Leboullaire C., Vander-Plancke J., Escudier B., Triebel F. Low - dose IL-2 treatment: activation of discrete T and NK-cell subpopulations in vivo. Int. J. Cancer 1995; 62: 523–528
   PubMed Web of Science ®Google Scholar
• Economon J. S., Hoban M., Lee J. D., Essner R., Swisher S., McBride W., Hoon D. B., Morton D. L. Production of tumor necrosis factor and interferon-y in interleukin-2 treated patients: correlation with clinical toxicity. Cancer Immunol. Immunother. 1991; 34: 49–53
   PubMed Web of Science ®Google Scholar
• Gusella G. L., Musso T., Bosco M. C., Espinoza-Delgado J., Matsushima K., Varesio L. IL-2-up-regulates but IFN γ supressess IL-8 expression in human monocytes. J. Immunol. 1993; 151: 2725–2732
   PubMed Web of Science ®Google Scholar
• Larsson L. G., Carlson M., Schena M., Lantz M., Cali-garis-Cappio F., Nilson K. IL-2 enhances the production of TNF-α in activated B-cells. Leukemia 1993; 7: 226–234
   PubMed Web of Science ®Google Scholar
• Nedwin G. E., Svedersky I. P., Bringman T. S., Paladino M. A., Goeddel D. V. Effect of interleukin 2, interferon γ and mitogens on the production of tumor necrosis factors α and b˜. J. Immunol. 1985; 135: 2492–2495
   PubMed Web of Science ®Google Scholar
• Numerof R. P., Aronson F. R., Mier J. W. IL-2 stimulates the production of IL- lα and IL-1b˜ by human perpheral blood mononuclear cells. J. Immunol. 1988; 141: 4250–4257
   PubMed Web of Science ®Google Scholar
• Dmoszynska A, Rolinski J. Interleukin 2 receptor (IL-2R): Stiucture and function. Acta Haemat. Pol. 1995; 26: 257–261
   PubMedGoogle Scholar
• Rubin LA, Nelson D. L. The soluble interleukin-2 receptors: biology. function and clinical application. Ann. Inter. Med. 1990; 113: 619–627
   PubMed Web of Science ®Google Scholar
• Voss S. D., Sondel P. M., Robb R. J. Characterization of interleukin 2 receptors (L2R) expressed on human natural killer cells activated in vitro by IL-2. Exp. Med. 1992; 176: 531–541
   PubMed Web of Science ®Google Scholar
• Rubin L. A., Kurman M., Fritz E., Biddison W. E., Boutin B., Yarchoan R., Nelson D. L. Soluble interleukin 2 receptors are released from activated lymphoid cells in vitro. J. Immunol. 1985; 135: 3172–3177
   PubMed Web of Science ®Google Scholar
• Aulitzky W. E., Schuler M., Peschel C., Huber C. Interleukins. Clinical pharmacology and therapeutic use. Drugs 1994; 48: 667–677
   Google Scholar
• Robak T. Cytokines in the treatment of hematological disorders: recent progress and perspectives. Arch. Immunol. Ther. Exp. 1996; 44: 5–9
   PubMedGoogle Scholar
• Lindenmann A., Brossart P., Höffken K., Flasshove M., Voli-Otis D., Diehl V., Hecker G., Wagner H., Mertelsmann R. Immunomodulatory effects of ultra-low-dose interleukin 2 in cancer patients: a phase IB study. Cancer Immunol. Immunother. 1993; 37: 307–315
   PubMed Web of Science ®Google Scholar
• Lindenmann A., Brossart P., Hoffken K., Flasshove M., Voli-Otis D., Diehl V., Kulmburg P., Wagner H., Mertelsmann R. Serum cytokine levels in cancer patients treated with different schedules of ultra-low-dose interleukin 2. J. Immunother. 1994; 15: 225–230
   Web of Science ®Google Scholar
• Meropol N. J., Porter M., Perez R. P., Vaickus L., Loewen G. M., Craven P. J., Wilkes K. A., Caliguri M. A. Low doses of interleukin 2: Daily subcutaneous injection results in selective in vivo expansion of natural killer (NK) cells with minimal toxicity. Proc ASCO 1994; 13: 965–967
   Google Scholar
• Peest D., Leo R., Bloche S., Hein B., Stannat-Kiessling S., Tschechne B., Fett W., Harms P., Hoffmann L., Bad R., Wacker H. H., Gorg S., Atzpodien J., Kirchner H., Deicher H. Low-dose recombinant interleukin-2 therapy in advanced multiple myeloma. Brit. J. Haematol. 1995; 89: 328–337
   PubMed Web of Science ®Google Scholar
• Chronic Leukemia-Myeloma Task Force, National Cancer Institute. Proposed guidelines for protocol studies. Cancer Chemother. Rep. 1973; 4: 145–152
   Google Scholar
• Daniluk J., Kandefer-Szerszeh M. Interferon production by peripheral blood cells of patients with alcoholic liver disease (ALD). Arch. Immunol. Ther. Exp. 1994; 42: 231–238
   PubMedGoogle Scholar
• Mossman T. Rapid colorimetric method for cellular growth and cytotoxicity assay. J. Immunol. Meth. 1983; 65: 55–63
   PubMed Web of Science ®Google Scholar
• Gisselbrecht C., Maraminchi D., Pico J. L., Milpied N., Coifier B., Divine M., Tiberghien P., Bosly A., Elly H., Boulat O., Brandely M. Interleukin-2 treatment in lymphoma: A phase II multicenter study. Blood 1994; 83: 2081–2085
   PubMed Web of Science ®Google Scholar
• Hussein M. A., Synder J., Rayman P., Lichtin A., McLain D. A., Finke J., Bukowski R. M. IL-2 maintenance therapy in multiple myeloma: a preliminary clinical report. Proc ASCO 1997; 13: 114
   Google Scholar
• Nagler A., Ackerstein A., Or R., Naparstek E., Slawin S. Immunotherapy with recombinant human interleukin-2 and recombinant interferon α in lymphoma postautolo-gous marrow or stem cell transplantation. Blood 1997; 89: 3951–3959
   PubMed Web of Science ®Google Scholar
• Rolnski J., Legiec W., Dmoszynska A. Influence of low doses subcutaneous IL-2 therapy on NK cell population in' patients with haematological malignancies. Ann. M. Curie- Sktodowska Univ. 1996; 51: 143–148
   Google Scholar
• Williams J. G., Jurkovich G. J., Maier R. V. Current research review. Interferon γ a key immunoregulatory lym-phokine. J. Surg. Res. 1993; 54: 79–93
   Google Scholar
• Foa R., Massaia M., Cardona S., Tos A. G., Bianchi A., Atti-Sano C, Guarini A., di Celle P. E., Fierro M. T. Production of TNF-α by B-cell CLL a possible regulatory role of TNF in the progression of the disease. Blood 1990; 76: 393–400
   PubMed Web of Science ®Google Scholar
• Agganval B. B., Kohr W. J. Human tumor necrosis factor. Production, purification and characterization. J. Biol. Chem. 1985; 260: 2345–2354
   Google Scholar
• Steinberger J., Beubassat H., Hochberg E., Lorberboumgal-Ski H. Interleukin-2 (IL-2) receptor alpha, beta and gamma subunit expression as a function of B-cell lineage ontogeny: the use of IL-2 PE66 (4 Glu) to characterize inter-nalization via IL-2 receptor subunits. Scand. J. Immunol. 1997; 46: 129–136
   PubMed Web of Science ®Google Scholar
• Semenzano G., Foa R., Agostini C., Zambello R., Trentin L., Vinante F., Benedetti M., Chilosi M., Pizzolo G. High serum levels of soluble interleukin 2 receptor in patients with chronic lymphocytic leukemia. Blood 1987; 70: 396–400
   PubMed Web of Science ®Google Scholar
• Zwierzina H., Herold M., Schollenberger S., Geisler D., Schmalzl. detection of soluble IL-2 receptor in serum of patients with myelodysplastic syndromes: induction under therapy with GM-CSF. Brit. 1. Haematol. 1991; 79: 438–443
   PubMed Web of Science ®Google Scholar
• Pui C. H., Ip S. H., Kung P., Dodge R. K., Berard C. W., Crist W. M., Murphy S. B. High serum interleukin 2 receptor levels are related to advanced disease and poor outcome in childhood non-Hodgkin's lymphoma. Blood. 1987; 70: 624–628
   PubMed Web of Science ®Google Scholar
• Pui C. H., Ip S. H., Iflash S., Behm F. G., Grose B. H., Dodge R. K., Crist W. M., Furman W. L., Murphy S. B., Riviera G. K. Serum interleukin 2 receptor levels in childhood acute lymphoblastic leukemia. Blood 1988; 71: 1135–1137
   PubMed Web of Science ®Google Scholar